{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:35Z","timestamp":1787199995805,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"DOI":"10.7759\/cureus.114815","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:21:46Z","timestamp":1787199706000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) on Staging, Biochemical Recurrence Detection, and Treatment Decision-Making in Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Saad","family":"Aad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribal","family":"Houmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Houmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Sassounian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Houmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel RL","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019, 69:7-34. 10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.169755","article-title":"11C- or 18F-Choline PET\/CT for imaging evaluation of biochemical recurrence of prostate cancer","volume":"57","author":"Mapelli P","year":"2016","unstructured":"Mapelli P, Incerti E, Ceci F, Castellucci P, Fanti S, Picchio M. 11C- or 18F-Choline PET\/CT for imaging evaluation of biochemical recurrence of prostate cancer. J Nucl Med. 2016, 57:43S-8S. 10.2967\/jnumed.115.169755","journal-title":"J Nucl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4089-x","article-title":"Diagnostic performance of (18)F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"45","author":"Rahbar K","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Sch\u00e4fers M, B\u00f6gemann M, Weckesser M. Diagnostic performance of (18)F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018, 45:2055-61. 10.1007\/s00259-018-4089-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels AM","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RA, Adang EM, et al.. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008, 63:387-95. 10.1016\/j.crad.2007.05.022","journal-title":"Clin Radiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht MK","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025, 22:26-45. 10.1038\/s41585-024-00900-z","journal-title":"Nat Rev Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.831429","article-title":"PSMA PET in imaging prostate cancer","volume":"12","author":"Tsechelidis I","year":"2022","unstructured":"Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Front Oncol. 2022, 12:831429. 10.3389\/fonc.2022.831429","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001792","article-title":"Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study","volume":"45","author":"Kaur K","year":"2024","unstructured":"Kaur K, Nagi S, Satapathy S, Aggarwal P, Sood A, Mittal BR. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study. Nucl Med Commun. 2024, 45:115-20. 10.1097\/MNM.0000000000001792","journal-title":"Nucl Med Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-025-02015-w","article-title":"Current insights on PSMA PET\/CT in intermediate-risk prostate cancer: a literature review","volume":"39","author":"Guglielmo P","year":"2025","unstructured":"Guglielmo P, Buffi N, Porreca A, Setti L, Aric\u00f2 D, Muraglia L, Evangelista L. Current insights on PSMA PET\/CT in intermediate-risk prostate cancer: a literature review. Ann Nucl Med. 2025, 39:247-54. 10.1007\/s12149-025-02015-w","journal-title":"Ann Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16872","article-title":"Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer","volume":"136","author":"Carll J","year":"2025","unstructured":"Carll J, Shi W, Perera M, Lawrentschuk N, Chengodu T, Woon D. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer. BJU Int. 2025, 136:800-4. 10.1111\/bju.16872","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment","volume":"87","author":"Mazzone E","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, et al.. A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol. 2025, 87:654-71. 10.1016\/j.eururo.2025.03.003","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman MS","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al.. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020, 395:1208-16. 10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis","volume":"24","author":"Satapathy S","year":"2021","unstructured":"Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021, 24:880-90. 10.1038\/s41391-021-00349-w","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang Y","year":"2022","unstructured":"Wang Y, Galante JR, Haroon A, et al.. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat Rev Urol. 2022, 19:475-93. 10.1038\/s41585-022-00618-w","journal-title":"Nat Rev Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta KJ","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, et al.. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021, 206:52-61. 10.1097\/JU.0000000000001698","journal-title":"J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.06.012","article-title":"A prospective comparison of (18)F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE)","volume":"4","author":"Anttinen M","year":"2021","unstructured":"Anttinen M, Ettala O, Malaspina S, et al.. A prospective comparison of (18)F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol. 2021, 4:635-44. 10.1016\/j.euo.2020.06.012","journal-title":"Eur Urol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of (68)ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten J","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, et al.. Head-to-head comparison of (68)ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020, 61:527-32. 10.2967\/jnumed.119.234187","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Chow KM","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, et al.. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023, 84:36-48. 10.1016\/j.eururo.2023.03.001","journal-title":"Eur Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2020.12.001","article-title":"Prostate-specific membrane antigen PET for assessment of primary and recurrent prostate cancer with histopathology as reference standard: a systematic review and meta-analysis","volume":"16","author":"Hernes E","year":"2021","unstructured":"Hernes E, Revheim ME, Hole KH, Tulipan AJ, Str\u00f8mme H, Lilleby W, Seierstad T. Prostate-specific membrane antigen PET for assessment of primary and recurrent prostate cancer with histopathology as reference standard: a systematic review and meta-analysis. PET Clin. 2021, 16:147-65. 10.1016\/j.cpet.2020.12.001","journal-title":"PET Clin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00161","article-title":"Transcriptomic profiling of primary prostate cancers and nonlocalized disease on prostate-specific membrane antigen positron emission tomography\/computed tomography: a multicenter retrospective study","volume":"8","author":"Nikitas J","year":"2024","unstructured":"Nikitas J, Subramanian K, Gozal NB, et al.. Transcriptomic profiling of primary prostate cancers and nonlocalized disease on prostate-specific membrane antigen positron emission tomography\/computed tomography: a multicenter retrospective study. JCO Precis Oncol. 2024, 8:e2400161. 10.1200\/PO.24.00161","journal-title":"JCO Precis Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.08.001","article-title":"Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard","volume":"5","author":"Stabile A","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E, et al.. Can negative prostate-specific membrane antigen positron emission tomography\/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022, 5:1-17. 10.1016\/j.euo.2021.08.001","journal-title":"Eur Urol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221105018","article-title":"Role of molecular imaging in the detection of localized prostate cancer","volume":"14","author":"Galgano SJ","year":"2022","unstructured":"Galgano SJ, West JT, Rais-Bahrami S. Role of molecular imaging in the detection of localized prostate cancer. Ther Adv Urol. 2022, 14:17562872221105018. 10.1177\/17562872221105018","journal-title":"Ther Adv Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis","volume":"53","author":"Jeet V","year":"2023","unstructured":"Jeet V, Parkinson B, Song R, Sharma R, Hoyle M. Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis. Semin Nucl Med. 2023, 53:706-18. 10.1053\/j.semnuclmed.2023.02.006","journal-title":"Semin Nucl Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01181-9","article-title":"Impact of PSMA PET on prostate cancer management","volume":"25","author":"Weiner AB","year":"2024","unstructured":"Weiner AB, Agrawal R, Valle LF, et al.. Impact of PSMA PET on prostate cancer management. Curr Treat Options Oncol. 2024, 25:191-205. 10.1007\/s11864-024-01181-9","journal-title":"Curr Treat Options Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong WR","year":"2024","unstructured":"Armstrong WR, Kishan AU, Booker KM, et al.. Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774). Eur Urol. 2024, 86:52-60. 10.1016\/j.eururo.2024.01.012","journal-title":"Eur Urol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer","volume":"83","author":"Bukavina L","year":"2023","unstructured":"Bukavina L, Luckenbaugh AN, Hofman MS, et al.. Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer. Eur Urol. 2023, 83:521-33. 10.1016\/j.eururo.2022.10.024","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.01.014","article-title":"Metastatic sites' location and impact on patient management after the introduction of prostate-specific membrane antigen positron emission tomography in newly diagnosed and biochemically recurrent prostate cancer: a critical review","volume":"6","author":"Mattana F","year":"2023","unstructured":"Mattana F, Muraglia L, Rajwa P, et al.. Metastatic sites' location and impact on patient management after the introduction of prostate-specific membrane antigen positron emission tomography in newly diagnosed and biochemically recurrent prostate cancer: a critical review. Eur Urol Oncol. 2023, 6:128-36. 10.1016\/j.euo.2023.01.014","journal-title":"Eur Urol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.12.015","article-title":"Two-fraction versus five-fraction stereotactic body radiotherapy for intermediate-risk prostate cancer: the TOFFEE meta-analysis of individual patient data from four prospective trials","volume":"8","author":"Udovicich C","year":"2025","unstructured":"Udovicich C, Cheung P, Chu W, et al.. Two-fraction versus five-fraction stereotactic body radiotherapy for intermediate-risk prostate cancer: the TOFFEE meta-analysis of individual patient data from four prospective trials. Eur Urol Oncol. 2025, 8:763-73. 10.1016\/j.euo.2024.12.015","journal-title":"Eur Urol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.08.005","article-title":"Stage migration on prostate-specific membrane antigen positron emission tomography\/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the phase 2\/3 THUNDER trial","volume":"8","author":"Kleiburg F","year":"2025","unstructured":"Kleiburg F, Dirix P, Fonteyne V, et al.. Stage migration on prostate-specific membrane antigen positron emission tomography\/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the phase 2\/3 THUNDER trial. Eur Urol Oncol. 2025, 8:1333-9. 10.1016\/j.euo.2025.08.005","journal-title":"Eur Urol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"26","author":"Pozdnyakov A","year":"2023","unstructured":"Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023, 26:240-8. 10.1038\/s41391-022-00544-3","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris MJ","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al.. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021, 27:3674-82. 10.1158\/1078-0432.CCR-20-4573","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2021.12.008","article-title":"The impact of PSMA PET\/CT imaging in prostate cancer radiation treatment","volume":"52","author":"Mena E","year":"2022","unstructured":"Mena E, Lindenberg L, Choyke P. The impact of PSMA PET\/CT imaging in prostate cancer radiation treatment. Semin Nucl Med. 2022, 52:255-62. 10.1053\/j.semnuclmed.2021.12.008","journal-title":"Semin Nucl Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2023.08.044","article-title":"Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies","volume":"31","author":"Wu Q","year":"2024","unstructured":"Wu Q, Bates A, Guntur P, Shamim SA, Nabi G. Detection rate of PSMA PET using different ligands in men with biochemical recurrent prostate cancer following radical treatment: a systematic review and meta-analysis of prospective studies. Acad Radiol. 2024, 31:544-63. 10.1016\/j.acra.2023.08.044","journal-title":"Acad Radiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z","article-title":"(68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler WP","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al.. (68)Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017, 44:1014-24. 10.1007\/s00259-017-3670-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13616","article-title":"The use of (68\u00a0) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","volume":"118 Suppl 3","author":"Meredith G","year":"2016","unstructured":"Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T. The use of (68\u00a0) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016, 118 Suppl 3:49-55. 10.1111\/bju.13616","journal-title":"BJU Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07292-1","article-title":"PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007","volume":"52","author":"Burgard C","year":"2025","unstructured":"Burgard C, Frei M, Blickle A, et al.. PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025, 52:4368-76. 10.1007\/s00259-025-07292-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001557","article-title":"Role of 68Ga and 18F PSMA PET\/CT and PET\/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies","volume":"43","author":"Mazrani W","year":"2022","unstructured":"Mazrani W, Cook GJ, Bomanji J. Role of 68Ga and 18F PSMA PET\/CT and PET\/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. Nucl Med Commun. 2022, 43:631-7. 10.1097\/MNM.0000000000001557","journal-title":"Nucl Med Commun"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck S","year":"2017","unstructured":"Schmuck S, Nordlohne S, von Klot CA, et al.. Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017, 44:960-8. 10.1007\/s00259-017-3669-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132249","article-title":"Tumor segmentation on PSMA PET\/CT predicts survival in biochemical recurrence of prostate cancer: a retrospective study using [(68)ga]ga-PSMA-11 and [(18)F]-PSMA-1007","volume":"17","author":"Kudura K","year":"2025","unstructured":"Kudura K, Schaulin Y, Templeton AJ, et al.. Tumor segmentation on PSMA PET\/CT predicts survival in biochemical recurrence of prostate cancer: a retrospective study using [(68)ga]ga-PSMA-11 and [(18)F]-PSMA-1007. Cancers (Basel). 2025, 17:2249. 10.3390\/cancers17132249","journal-title":"Cancers (Basel)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2025.05.004","article-title":"PSMA-PET guided radiotherapy in prostate cancer: a critical review of current applications and future directions","volume":"35","author":"Dragonetti V","year":"2025","unstructured":"Dragonetti V, Colandrea M, Travaini L, Air\u00f2 Farulla LS, Ceci F, Mattana F. PSMA-PET guided radiotherapy in prostate cancer: a critical review of current applications and future directions. Semin Radiat Oncol. 2025, 35:317-24. 10.1016\/j.semradonc.2025.05.004","journal-title":"Semin Radiat Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246194","article-title":"Management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of PSMA PET","volume":"14","author":"Sabbagh A","year":"2022","unstructured":"Sabbagh A, Mohamad O, Lichter KE, Hope TA. Management of patients with recurrent and metachronous oligometastatic prostate cancer in the era of PSMA PET. Cancers (Basel). 2022, 14:6194. 10.3390\/cancers14246194","journal-title":"Cancers (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2022.825512","article-title":"Normal variants, pitfalls, and artifacts in Ga-68 prostate specific membrane antigen (PSMA) PET\/CT imaging","volume":"2","author":"Malan N","year":"2022","unstructured":"Malan N, Vangu MD. Normal variants, pitfalls, and artifacts in Ga-68 prostate specific membrane antigen (PSMA) PET\/CT imaging. Front Nucl Med. 2022, 2:825512. 10.3389\/fnume.2022.825512","journal-title":"Front Nucl Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [(177)lu]lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data","volume":"65","author":"Murthy V","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, et al.. Efficacy and toxicity of [(177)lu]lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data. J Nucl Med. 2024, 65:1740-4. 10.2967\/jnumed.124.267816","journal-title":"J Nucl Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021204506","article-title":"Multiparametric MRI of the prostate: beyond cancer detection and staging","volume":"299","author":"Costa DN","year":"2021","unstructured":"Costa DN. Multiparametric MRI of the prostate: beyond cancer detection and staging. Radiology. 2021, 299:624-5. 10.1148\/radiol.2021204506","journal-title":"Radiology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2019.02.006","article-title":"Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls","volume":"49","author":"Sheikhbahaei S","year":"2019","unstructured":"Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. Semin Nucl Med. 2019, 49:255-70. 10.1053\/j.semnuclmed.2019.02.006","journal-title":"Semin Nucl Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06797-5","article-title":"The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition","volume":"51","author":"Rizzo A","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, et al.. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024, 51:3753-64. 10.1007\/s00259-024-06797-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05616-5","article-title":"(68)Ga-PSMA PET in prostate cancer: a systematic review and\u00a0meta-analysis\u00a0of the\u00a0observer agreement","volume":"49","author":"Chavoshi M","year":"2022","unstructured":"Chavoshi M, Mirshahvalad SA, Metser U, Veit-Haibach P. (68)Ga-PSMA PET in prostate cancer: a systematic review and\u00a0meta-analysis\u00a0of the\u00a0observer agreement. Eur J Nucl Med Mol Imaging. 2022, 49:1021-9. 10.1007\/s00259-021-05616-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102355","article-title":"Prognostic role of PSMA-targeted imaging in metastatic castration-resistant prostate cancer: an overview","volume":"12","author":"Caracciolo M","year":"2024","unstructured":"Caracciolo M, Castello A, Castellani M, Bartolomei M, Lopci E. Prognostic role of PSMA-targeted imaging in metastatic castration-resistant prostate cancer: an overview. Biomedicines. 2024, 12:2355. 10.3390\/biomedicines12102355","journal-title":"Biomedicines"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267606","article-title":"Comparison of posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT\/CT and pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Swiha M","year":"2024","unstructured":"Swiha M, Pathmanandavel S, Papa N, et al.. Comparison of posttherapy 4- and 24-Hour [(177)Lu]Lu-PSMA SPECT\/CT and pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer. J Nucl Med. 2024, 65:1939-44. 10.2967\/jnumed.124.267606","journal-title":"J Nucl Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2647","article-title":"New perspectives on metabolic imaging in the management of prostate cancer in 2022: a focus on radiolabeled PSMA\u2011PET\/CT (Review)","volume":"19","author":"Simon H","year":"2023","unstructured":"Simon H, Henkel D, Chiron P, Helissey C. New perspectives on metabolic imaging in the management of prostate cancer in 2022: a focus on radiolabeled PSMA\u2011PET\/CT (Review). Mol Clin Oncol. 2023, 19:51. 10.3892\/mco.2023.2647","journal-title":"Mol Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050710","article-title":"Detection rate of (18)F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis","volume":"11","author":"Treglia G","year":"2019","unstructured":"Treglia G, Annunziata S, Pizzuto DA, Giovanella L, Prior JO, Ceriani L. Detection rate of (18)F-labeled PSMA PET\/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel). 2019, 11:710. 10.3390\/cancers11050710","journal-title":"Cancers (Basel)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts MJ","year":"2023","unstructured":"Roberts MJ, Maurer T, Perera M, et al.. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023, 20:23-47. 10.1038\/s41585-022-00670-6","journal-title":"Nat Rev Urol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12121982","article-title":"1.5T MR-guided daily-adaptive SBRT for prostate cancer: preliminary report of toxicity and quality of life of the first 100 patients","volume":"12","author":"Alongi F","year":"2022","unstructured":"Alongi F, Rigo M, Figlia V, et al.. 1.5T MR-guided daily-adaptive SBRT for prostate cancer: preliminary report of toxicity and quality of life of the first 100 patients. J Pers Med. 2022, 12:1982. 10.3390\/jpm12121982","journal-title":"J Pers Med"},{"key":"ref53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.5018","article-title":"68Ga-PSMA PET\/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): results of a prospective study","volume":"42","author":"Giunta EF","year":"2024","unstructured":"Giunta EF, Caroli P, Scarpi E, et al.. 68Ga-PSMA PET\/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): results of a prospective study. J Clin Oncol. 2024, 42:5018.","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert R","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al.. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023, 83:405-12. 10.1016\/j.eururo.2023.02.002","journal-title":"Eur Urol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau JP","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, et al.. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022, 23:1389-97. 10.1016\/S1470-2045(22)00605-2","journal-title":"Lancet Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett L","year":"2025","unstructured":"Emmett L, Papa N, Subramaniam S, et al.. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025, 26:1168-77. 10.1016\/S1470-2045(25)00339-0","journal-title":"Lancet Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267306","article-title":"Interreader and intrareader reproducibility of (18)F-flotufolastat image interpretation in patients with newly diagnosed or recurrent prostate cancer: data from two phase 3 prospective multicenter studies","volume":"65","author":"Kuo PH","year":"2024","unstructured":"Kuo PH, Esposito G, Ulaner GA, et al.. Interreader and intrareader reproducibility of (18)F-flotufolastat image interpretation in patients with newly diagnosed or recurrent prostate cancer: data from two phase 3 prospective multicenter studies. J Nucl Med. 2024, 65:1239-43. 10.2967\/jnumed.123.267306","journal-title":"J Nucl Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268071","article-title":"Treatment response evaluation in prostate cancer using PSMA PET\/CT","volume":"66","author":"Gafita A","year":"2025","unstructured":"Gafita A, Schroeder JA, Ceci F, et al.. Treatment response evaluation in prostate cancer using PSMA PET\/CT. J Nucl Med. 2025, 66:995-1004. 10.2967\/jnumed.124.268071","journal-title":"J Nucl Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.06.001","article-title":"Applications of artificial intelligence in PSMA PET\/CT for prostate cancer imaging","volume":"54","author":"Lindgren Belal S","year":"2024","unstructured":"Lindgren Belal S, Frantz S, Minarik D, Enqvist O, Wikstr\u00f6m E, Edenbrandt L, Tr\u00e4g\u00e5rdh E. Applications of artificial intelligence in PSMA PET\/CT for prostate cancer imaging. Semin Nucl Med. 2024, 54:141-9. 10.1053\/j.semnuclmed.2023.06.001","journal-title":"Semin Nucl Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05473-2","article-title":"Whole-body uptake classification and prostate cancer staging in (68)Ga-PSMA-11 PET\/CT using dual-tracer learning","volume":"49","author":"Capobianco N","year":"2022","unstructured":"Capobianco N, Sibille L, Chantadisai M, et al.. Whole-body uptake classification and prostate cancer staging in (68)Ga-PSMA-11 PET\/CT using dual-tracer learning. Eur J Nucl Med Mol Imaging. 2022, 49:517-26. 10.1007\/s00259-021-05473-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103318","article-title":"The role of radiomics and artificial intelligence applied to staging PSMA PET in assessing prostate cancer aggressiveness","volume":"14","author":"Urso L","year":"2025","unstructured":"Urso L, Badrane I, Manco L, et al.. The role of radiomics and artificial intelligence applied to staging PSMA PET in assessing prostate cancer aggressiveness. J Clin Med. 2025, 14:3318. 10.3390\/jcm14103318","journal-title":"J Clin Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.22038\/AOJNMB.2022.64964.1454","article-title":"Therapeutic outcomes of (177)lu-PSMA targeted therapy in patients with metastatic castration-resistant prostate cancer: a single-center study","volume":"11","author":"Mirshahvalad SA","year":"2023","unstructured":"Mirshahvalad SA, Farzanefar S, Abbasi M. Therapeutic outcomes of (177)lu-PSMA targeted therapy in patients with metastatic castration-resistant prostate cancer: a single-center study. Asia Ocean J Nucl Med Biol. 2023, 11:23-9. 10.22038\/AOJNMB.2022.64964.1454","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.96226","article-title":"Artificial intelligence across the prostate cancer pathway: screening, imaging, pathology, and biomarkers","volume":"17","author":"Hasan MR","year":"2025","unstructured":"Hasan MR, Ibraheem N, Rahman ME, Tamanna R. Artificial intelligence across the prostate cancer pathway: screening, imaging, pathology, and biomarkers. Cureus. 2025, 17:e96226. 10.7759\/cureus.96226","journal-title":"Cureus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.929444","article-title":"Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer","volume":"12","author":"Alberto M","year":"2022","unstructured":"Alberto M, Yim A, Papa N, et al.. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol. 2022, 12:929444. 10.3389\/fonc.2022.929444","journal-title":"Front Oncol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman MS","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018, 38:200-17. 10.1148\/rg.2018170108","journal-title":"Radiographics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494337-clinical-impact-of-prostate-specific-membrane-antigen-positron-emission-tomography-psma-pet-on-staging-biochemical-recurrence-detection-and-treatment-decision-making-in-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:21:48Z","timestamp":1787199708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494337-clinical-impact-of-prostate-specific-membrane-antigen-positron-emission-tomography-psma-pet-on-staging-biochemical-recurrence-detection-and-treatment-decision-making-in-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":65,"URL":"https:\/\/doi.org\/10.7759\/cureus.114815","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}